 Point Biopharma Global Inc NASDAQ: PNT has additional preclinical data from its fibroblast activation protein-alpha FAP-alpha inhibitor program, PNT2004. The new data demonstrate rapid and persistent tumor targeting with very low retention in normal tissues. 